Reporting Hormone Receptor Expression in Breast Carcinomas: Which Method has the Highest Prognostic Power and What Should be the Optimal Cut-off Value?

被引:0
作者
Ozturk, Cigdem [1 ]
Okcu, Oguzhan [2 ]
Ozturk, Seda Duman [3 ]
Sen, Bayram [4 ]
Ozturk, Ahmet Emin [5 ]
Bedir, Recep [2 ]
机构
[1] Recep Tayyip Erdogan Univ, Training & Res Hosp, Pathol Dept, Rize, Turkiye
[2] Recep Tayyip Erdog?an Univ, Fac Med, Pathol Dept, Rize, Turkiye
[3] Kocaeli Univ, Pathol Dept, Fac Med, Izmit, Turkiye
[4] Recep Tayyip Erdogan Univ, Biochem Dept, Training & Res Hosp, Rize, Turkiye
[5] Hlth Sci Univ, Prof Dr Cemil Tascioglu City Hosp, Med Oncol Dept, Istanbul, Turkiye
关键词
estrogen receptor; progesterone receptor; reporting systems; prognostic power; cut-off value; GENE-EXPRESSION; PROGESTERONE-RECEPTORS; ESTROGEN; CANCER; POSITIVITY; EXPERIENCE; SUBTYPES; KI-67;
D O I
10.1177/10668969241265068
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background . Hormone receptor (HR) expression is a critical marker that plays a role in the treatment and management of breast cancer. Even if patients receive hormone treatment with a hormone positivity rate of over 1%, it is controversial at what level of positivity they benefit from treatment and contribute positively to their prognosis. Methods . We retrospectively examined the estrogen receptor (ER) / progesterone receptor (PR) expression status, clinicopathological findings, and survival data of 386 patients who underwent surgery for breast cancer. ER/PR expressions of the patients were evaluated according to Allred, H-score and were also grouped according to staining percentages. Separate cut-off values were determined for each of these evaluation methods, and the prognostic power of these methods was investigated using receiver operating characteristic analysis. Results . The prognostic power of all methods was found to be similar in terms of predicting survival. According to the staining percentage of the patients, survival was excellent if the ER value was >80% and the PR value was >1%. Conclusions . All recommended methods for reporting HRs have similar prognostic power. However, in patients with high percentage staining for ER using these methods, the prognosis is excellent. As a result, we predict that if the percentage of ER staining is low, changing the treatment management of patients may be considered clinically.
引用
收藏
页码:353 / 362
页数:10
相关论文
共 33 条
[1]   Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].
Albain, Kathy S. ;
Barlow, William E. ;
Shak, Steven ;
Hortobagyi, Gabriel N. ;
Livingston, Robert B. ;
Yeh, I-Tien ;
Ravdin, Peter ;
Bugarini, Roberto ;
Boehner, Frederick L. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Winer, Eric P. ;
Hudis, Clifford ;
Ingle, James N. ;
Perez, Edith A. ;
Pritchard, Kathleen I. ;
Shepherd, Lois ;
Gralow, Julie R. ;
Yoshizawa, Carl ;
Allred, D. Craig ;
Osborne, C. Kent ;
Hayes, Daniel F. .
LANCET ONCOLOGY, 2010, 11 (01) :55-65
[2]   Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update [J].
Allison, Kimberly H. ;
Hammond, M. Elizabeth H. ;
Dowsett, Mitchell ;
McKernin, Shannon E. ;
Carey, Lisa A. ;
Fitzgibbons, Patrick L. ;
Hayes, Daniel F. ;
Lakhani, Sunil R. ;
Chavez-MacGregor, Mariana ;
Perlmutter, Jane ;
Perou, Charles M. ;
Regan, Meredith M. ;
Rimm, David L. ;
Symmans, W. Fraser ;
Torlakovic, Emina E. ;
Varella, Leticia ;
Viale, Giuseppe ;
Weisberg, Tracey F. ;
McShane, Lisa M. ;
Wolff, Antonio C. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1346-+
[3]   Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance [J].
Arpino, G ;
Weiss, H ;
Lee, AV ;
Schiff, R ;
De Placido, S ;
Osborne, CK ;
Elledge, RM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1254-1261
[4]   Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer [J].
Bae, Soo Youn ;
Kim, Sangmin ;
Lee, Jun Ho ;
Lee, Hyun-chul ;
Lee, Se Kyung ;
Kil, Won Ho ;
Kim, Seok Won ;
Lee, Jeong Eon ;
Nam, Seok Jin .
BMC CANCER, 2015, 15
[5]   Breast Carcinoma Updates in Molecular Profiling 2018 [J].
Bandyopadhyay, Sudeshna ;
Bluth, Martin H. ;
Ali-Fehmi, Rouba .
CLINICS IN LABORATORY MEDICINE, 2018, 38 (02) :401-+
[6]  
Brookland RK, 2017, AJCC Cancer Staging Manual, V8th
[7]   Association between low estrogen receptor positive breast cancer and staining performance [J].
Caruana, Dennis ;
Wei, Wei ;
Martinez-Morilla, Sandra ;
Rimm, David L. ;
Reisenbichler, Emily S. .
NPJ BREAST CANCER, 2020, 6 (01)
[8]   Effect of Ki-67 on Immunohistochemical Classification of Luminal A to Luminal B Subtypes of Breast Carcinoma [J].
Cirqueira, Magno Belem ;
Reboucas Moreira, Marise Amaral ;
Soares, Leonardo Ribeiro ;
Carneiro Cysneiros, Maria-Auxiliadora de Paula ;
Vilela, Maria-Helena Tavares ;
Freitas-Junior, Ruffo .
BREAST JOURNAL, 2015, 21 (05) :465-472
[9]  
College of American Pathologists (CAP), 2020, Protocol for the examination of specimens from patients with carcinoma of the stomach
[10]   Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype [J].
Deyarmin, Brenda ;
Kane, Jennifer L. ;
Valente, Allyson L. ;
van Laar, Ryan ;
Gallagher, Christopher ;
Shriver, Craig D. ;
Ellsworth, Rachel E. .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (01) :87-93